Is Transcutaneous Spinal Direct Current Stimulation Efficient in Symptomatic Treatment of Patients with Idiopathic Restless Legs Syndrome? (P02.060)

CONCLUSIONS: Our data indicate that tsDCS is efficient in alleviating RLS symptoms and might become a completely new, non-pharmacological therapeutic tool for primary RLS patients.Supported by: German Restless Legs Syndrom patients' organization (RLS e.V.).Disclosure: Dr. Heide has nothing to disclose. Dr. Winkler has nothing to disclose. Dr. Nitsche has received personal compensation for activities with Neuroelectrics, Eisai, Inc., UCB Pharma, and GlaxoSmithKline, Inc. Dr. Nitsche has received research support from Eisai, Inc. UCB Pharma, and GlaxoSmithKline, Inc. Dr. Heide has received personal compensation for activities with Bayer and Sanofi-Aventis Pharmaceuticals, Inc. Dr. Trenkwalder has received personal compensation for activities with Boehringer Ingelheim Pharmaceuticals, Inc., Mundipharm, UCB Pharma, and Teva Neuroscience. Dr. Trenkwalder has received research support from Mundipharm and Novartis. Dr. Paulus has received personal compensation for activities with EBS technologies, Desitin, GlaxoSmithKline, UCB, PPD Germany GmbH, and Eisai. Dr. Paulus has received research support from Weber Medical. Dr. Bachmann has nothing to disclose.

Source: Neurology - February 14, 2013 Category: Neurology Authors: Heide, A.-C., Winkler, T., Nitsche, M., Heide, W., Trenkwalder, C., Paulus, W., Bachmann, C. Tags: P02 Restless Legs Syndrome, Tourette Syndrome, and Dystonia Source Type: research